Curevo Raises $110M Series B to Advance Shingles Vaccine Amid GSK Competition, Adds Former GSK and Moderna Execs to Board

Seattle biotech startup Curevo raised $110 million in a Series B round to advance Phase 2 trials of its shingles vaccine amezosvatein, competing with GlaxoSmithKline's Shingrix. The company added biotech veterans, including former GSK and Moderna executives, to its board to support development.

GGeorge Simeon CCurevo